Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2001
02/15/2001WO2001010887A2 Multi-functional antimicrobial peptides
02/15/2001WO2001010884A1 Drug target isogenes: polymorphisms in the 5-hydroxytryptamine receptor 1a gene
02/15/2001WO2001010883A1 Cell death gene and uses thereof
02/15/2001WO2001010845A1 Novel diketopiperazines
02/15/2001WO2001010799A1 Methods for preparing n-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds
02/15/2001WO2001010468A2 Drug-carrier complexes and methods of use thereof
02/15/2001WO2001010462A1 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
02/15/2001WO2001010458A1 Use of neurotoxin for treating cardiac muscle disorders
02/15/2001WO2001010457A2 Pharmaceutical compositions containing tripeptides
02/15/2001WO2001010456A2 Peptides that block viral infectivity and methods of use thereof
02/15/2001WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins
02/15/2001WO2001010454A2 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
02/15/2001WO2001010448A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
02/15/2001WO2001010446A2 Formulations for parenteral use of estramustine phosphate and albumin
02/15/2001WO2001010438A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids
02/15/2001WO2001010426A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer
02/15/2001WO2001010425A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
02/15/2001WO2001010421A1 Drug releasing biodegradable fiber implant
02/15/2001WO2001010414A1 Slow release microspheres
02/15/2001WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers
02/15/2001WO2001010411A2 Implantable active ingredient depot
02/15/2001WO2001010387A2 Antiviral therapy use of p-glycoprotein modulators
02/15/2001WO2001010386A2 Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
02/15/2001WO2001010384A2 Method for identifying compounds for treatment of insulin resistance
02/15/2001WO2001010382A2 Compositions and methods related to claudin-7
02/15/2001WO2001010205A1 Methods and materials relating to cd39-like polypeptides
02/15/2001WO2001010203A2 Non-human transgenic animals for the study of neurodegenerative syndromes
02/15/2001WO2001010199A1 A knockout mouse for the tumor suppressor gene anx7
02/15/2001WO2000070945A3 Fatty acid elongation genes and uses thereof
02/15/2001WO2000069900A3 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
02/15/2001WO2000069884A3 Compositions isolated from skin cells and methods for their use
02/15/2001WO2000068385A3 Novel nucleic acids and proteins with growth hormone activity
02/15/2001WO2000068384A3 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
02/15/2001WO2000068376B1 Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
02/15/2001WO2000068363A3 Elastase variants and substrates
02/15/2001WO2000068264A3 A peptide inhibitor of fibrinogen blood clotting
02/15/2001WO2000066709A3 Zymogen activation system
02/15/2001WO2000066067A3 Ibd-associated microbial antigens and methods of using same
02/15/2001WO2000065054A3 Human membrane-associated proteins
02/15/2001WO2000064957A3 Differentially acting op detoxifying sponges
02/15/2001WO2000062740A3 Skin care compositions containing combination of skin care actives
02/15/2001WO2000058456A3 Compositions and methods for modifying toxic effects of proteinacious compounds
02/15/2001WO2000057920A3 Method for expressing proteins
02/15/2001WO2000057900A3 Factor for regulation of neurite growth
02/15/2001WO2000056866A3 Akt-3 nucleic acids, polypeptides, and uses thereof
02/15/2001WO2000053167A3 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
02/15/2001WO2000044908A3 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
02/15/2001WO2000043419A3 Exocytosis pathway proteins and methods of use
02/15/2001WO2000039154A8 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension
02/15/2001WO2000032774A8 12216 receptor, a g-protein coupled receptor
02/15/2001WO2000012112A3 Treatment of lesions with xanthine oxidoreductase
02/15/2001WO2000011204A3 Homer interacting proteins
02/15/2001DE19938601A1 Use of thaumatin for flavor and aroma harmonization and modification in food, drink, pharmaceutical, tobacco, feedstuffs, cosmetics and diabetic products
02/15/2001DE19937846A1 New human gene BOCT, encoding an organic cation transporter, useful for diagnosis, treatment and development of pharmaceuticals
02/15/2001DE19937839A1 New human gene OLFXY, encoding an olfactory receptor, useful for diagnosis, treatment and development of pharmaceuticals
02/15/2001DE19937721A1 Neue Diketopiperazine New Diketopiperazines
02/15/2001DE19937656A1 Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen The use of antithrombin III for the prophylaxis and treatment of diseases
02/15/2001DE19935140A1 Neue Glykosyltransferase, ihre Herstellung und Verwendung New glycosyltransferase, their preparation and use
02/15/2001DE19908766C2 Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien Use of synthetic Vpr peptides of human immunodeficiency virus type 1 (HIV-1) for the development of therapeutic and diagnostic reagents
02/15/2001CA2388341A1 Non-human transgenic animals for the study of neurodegenerative syndromes
02/15/2001CA2382659A1 Dendritic enriched secreted lymphocyte activation molecule
02/15/2001CA2381607A1 Glucuronoxylomannan (gxm)-o-acetylhydrolase of cryptococcus neoformans and uses thereof
02/15/2001CA2381396A1 Polynucleotides and polypeptides encoded thereby
02/15/2001CA2381325A1 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy
02/15/2001CA2381293A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof
02/15/2001CA2381284A1 Fhm, a novel member of the tnf ligand supergene family
02/15/2001CA2381005A1 Therapeutic polypeptides and methods for using same
02/15/2001CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes
02/15/2001CA2380647A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
02/15/2001CA2380633A1 Peptide antagonists of factor viia
02/15/2001CA2380312A1 Formulations for parenteral use of estramustine phosphate and albumin
02/15/2001CA2379608A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
02/15/2001CA2379087A1 Antimicrobial histone h1 compositions, kits, and methods of use thereof
02/15/2001CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins
02/15/2001CA2378984A1 Antiviral therapy use of p-glycoprotein modulators
02/15/2001CA2378646A1 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
02/15/2001CA2378620A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
02/15/2001CA2378608A1 Compositions and methods related to claudin-7
02/15/2001CA2378480A1 Pharmaceutical compositions containing tripeptides
02/15/2001CA2378460A1 Peptides that block viral infectivity and methods of use thereof
02/15/2001CA2378401A1 Implantable active ingredient depot
02/15/2001CA2378292A1 A knockout mouse for the tumor suppressor gene anx7
02/15/2001CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof
02/15/2001CA2374745A1 Proteases and protease inhibitors
02/15/2001CA2346063A1 Composition and methods for treatment of hiv infection
02/14/2001EP1076092A2 Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents
02/14/2001EP1076091A1 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
02/14/2001EP1076066A1 Peptides for lowering blood glucose levels
02/14/2001EP1076065A1 Polypeptide having antihuman immunodeficiency virus activity, gene encoding the polypeptide and process for producing the polypeptide
02/14/2001EP1076062A1 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
02/14/2001EP1076056A1 Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same
02/14/2001EP1075840A2 Therapeutic and prophylactic uses of antithrombin III
02/14/2001EP1075837A2 Process for the preparation of aqueous formulations for ophthalmic use
02/14/2001EP1075673A1 Methods of determining protein activity levels using gene expression profiles
02/14/2001EP1075662A2 Methods for diagnosing and evaluating cancer
02/14/2001EP1075535A1 A method for diagnosing and treating chronic pelvic pain syndrome
02/14/2001EP1075528A1 Endothelin-converting-enzyme like protein
02/14/2001EP1075526A1 Putative lactamase proteins from mouse and human
02/14/2001EP1075520A1 Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
02/14/2001EP1075519A2 Inhibitors of nf-kb activation